CAU
SNDX icon

Caxton Associates (UK)’s Syndax Pharmaceuticals SNDX Stock Holding History

Caxton Associates (UK)’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,945
Closed -$257K – 900
2025
Q1 		$257K Buy
+20,945
New +$295K 0.01% 662

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Caxton Associates (UK)'s SNDX Position: Q2 2025 in Review

Caxton Associates (UK) sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 20,945 shares — an estimated $257K sold.

Caxton Associates (UK) first reported a position in SNDX in Q1 2025 and held it in 1 quarter. The position peaked at $257K in Q1 2025. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

  • Caxton Associates (UK) reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 20,945 Syndax Pharmaceuticals shares in Q2 2025, an estimated $257K.
  • Caxton Associates (UK) first reported a position in Syndax Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s Syndax Pharmaceuticals position peaked at $257K in Q1 2025.
  • 216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Caxton Associates (UK)'s 13F filing for Q2 2025, filed 15 Aug 2025.